Business Context and Reporting Period
This Form 6-K filing by NovaBridge Biosciences covers the period ending June 16, 2026. The report details a significant corporate governance change involving the dismissal of the company's independent registered public accounting firm and the appointment of a successor.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on auditor transition disclosures rather than financial performance data.
Material Changes
- Dismissal of PwC: On June 16, 2026, the Audit Committee approved the immediate dismissal of PricewaterhouseCoopers LLP (PwC) as the independent registered public accounting firm.
- Appointment of Deloitte: On the same date, the Audit Committee appointed Deloitte Touche Tohmatsu Certified Public Accountants LLP as the new independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Audit History: PwC's reports for fiscal years 2024 and 2025 contained no adverse opinions, disclaimers, or qualifications. There were no disagreements regarding accounting principles or auditing scope during these periods.
- Reportable Events: The only reportable events noted were material weaknesses related to ineffective information technology general controls (ITGCs) as of December 31, 2025, and December 31, 2024, previously disclosed in the company's Form 20-F annual reports.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, management commentary on future outlook, or new risk factors beyond the disclosed ITGC material weaknesses. The transition of auditors was executed without prior consultation with Deloitte regarding accounting principles or audit opinions for the periods in question.
Investor Verification Checklist
- Verify the status of remediation efforts for the material weaknesses in ITGCs disclosed in the 2024 and 2025 annual reports.
- Review the attached letter from PwC (Exhibit 16.1) to confirm their agreement with the company's disclosures regarding the dismissal.
- Monitor future filings for the initial audit opinion from Deloitte for the fiscal year ending December 31, 2026.
- Confirm that no undisclosed disagreements or reportable events exist between the company and the new auditor.